Clinical aspects of indirect immunofluorescence for autoimmune diseases

References

• Coons AH, Creech HJ, Jones RN. Immunological properties of an antibody containing a fluorescent group. Exp Biol Med 1941;47(2):200-2
   Google Scholar
• Agmon-Levin N, Damoiseaux J, Kallenberg C, et al. International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. Ann Rheum Dis 2014;73(1):17-23
   PubMed Web of Science ®Google Scholar
• Vermeersch P, Bossuyt X. Prevalence and clinical significance of rare antinuclear antibody patterns. Autoimmun Rev 2013;12(10):998-1003
   PubMed Web of Science ®Google Scholar
• Tozzoli R, Bizzaro N, Tonutti E, et al. Guidelines for the laboratory use of autoantibody tests in the diagnosis and monitoring of autoimmune rheumatic diseases. Am J Clin Pathol 2002;117(2):316-24
   PubMed Web of Science ®Google Scholar
• Ntatsaki E, Watts RA, Scott DGI. Epidemiology of ANCA-associated vasculitis. Rheum Dis Clin North Am 2010;36(3):447-61
   PubMed Web of Science ®Google Scholar
• Fujimoto S, Watts RA, Kobayashi S, et al. Comparison of the epidemiology of anti-neutrophil cytoplasmic antibody-associated vasculitis between Japan and the UK. Rheumatology 2011;50(10):1916-20
   PubMed Web of Science ®Google Scholar
• Bosch X, Guilabert A, Font J. Antineutrophil cytoplasmic antibodies. Lancet 2006;368(9533):404-18
   PubMed Web of Science ®Google Scholar
• Seo P, Stone JH. The antineutrophil cytoplasmic antibody–associated vasculitides. Am J Med 2004;117(1):39-50
   PubMed Web of Science ®Google Scholar
• Van der Woude FJ, Lobatto S, Permin H, et al. Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener’s granulomatosis. Lancet 1985;325(8426):425-9
   Google Scholar
• Falk RJ, Jennette JC. Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis. N Engl J Med 1988;318(25):1651-7
   PubMed Web of Science ®Google Scholar
• Jennette JC, Wilkman AS, Falk RJ. Anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and vasculitis. Am J Pathol 1989;135(5):921
   PubMed Web of Science ®Google Scholar
• Xiao H, Heeringa P, Hu P, et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 2002;110(7):955-63
   PubMed Web of Science ®Google Scholar
• Kallenberg CGM. Pathogenesis of ANCA-associated vasculitides. Ann Rheum Dis 2011;70(Suppl 1):i59-63
   Web of Science ®Google Scholar
• Charles JJ, Falk RJ. B cell-mediated pathogenesis of ANCA-mediated vasculitis. In: Seminars in immunopathology. Springer Berlin Heidelberg; 2014. p. 1-12
   Google Scholar
• Hagen EC, Daha MR, Hermans JO, et al. Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. Kidney Int 1998;53(3):743-53
   PubMed Web of Science ®Google Scholar
• Russell KA, Wiegert E, Schroeder DR, et al. Detection of anti-neutrophil cytoplasmic antibodies under actual clinical testing conditions. Clin Immunol 2002;103(2):196-203
   PubMed Web of Science ®Google Scholar
• Millet A, Pederzoli-Ribeil M, Guillevin L, et al. Antineutrophil cytoplasmic antibody-associated vasculitides: is it time to split up the group? Ann Rheum Dis 2013;72(8):1273-9
   PubMed Web of Science ®Google Scholar
• Savige J, Davies D, Falk RJ, et al. Antineutrophil cytoplasmic antibodies and associated diseases: a review of the clinical and laboratory features. Kidney Int 2000;57(3):846-62
   PubMed Web of Science ®Google Scholar
• Csernok E, Moosig F. Current and emerging techniques for ANCA detection in vasculitis. Nat Rev Rheumatol 2014;10(8):494-501
   PubMed Web of Science ®Google Scholar
• Martínez Téllez G, Torres Rives B, Rangel Velázquez S, et al. Antineutrophil cytoplasm antibody: positivity and clinical correlation. Reumatol Clin 2015. 11(1):17-21
   Google Scholar
• Savige J, Gillis D, Benson E, et al. International consensus statement on testing and reporting of antineutrophil cytoplasmic antibodies (ANCA). Am J Clin Pathol 1999;111(4):507-13
   PubMed Web of Science ®Google Scholar
• Savige J, Dimech W, Fritzler M, et al. Addendum to the International Consensus Statement on testing and reporting of antineutrophil cytoplasmic antibodies. Quality control guidelines, comments, and recommendations for testing in other autoimmune diseases. Am J Clin Pathol 2003;120(3):312-18
   PubMed Web of Science ®Google Scholar
• Lin M-W, Silvestrini RA, Culican S, et al. A dual-fixed neutrophil substrate improves interpretation of antineutrophil cytoplasmic antibodies by indirect immunofluorescence. Am J Clin Pathol 2014;142(3):325-30
   PubMed Web of Science ®Google Scholar
• Sowa M, Grossmann K, Knütter I, et al. Simultaneous automated screening and confirmatory testing for vasculitis-specific ANCA. PLoS One 2014;9(9):e107743
   Web of Science ®Google Scholar
• Sinico RA, Radice A. Antineutrophil cytoplasmic antibodies (ANCA) testing: detection methods and clinical application. Clin Exp Rheumatol 2014;32(3 Suppl 82):S112-17
   Google Scholar
• Radice A, Sinico RA. Antineutrophil cytoplasmic antibodies (ANCA). Autoimmunity 2005;38(1):93-103
   PubMed Web of Science ®Google Scholar
• Sinico RA, Di Toma L, Maggiore U, et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis Rheum 2005;52(9):2926-35
   PubMed Web of Science ®Google Scholar
• Wong RC, Silvestrini RA, Savige JA, et al. Diagnostic value of classical and atypical antineutrophil cytoplasmic antibody (ANCA) immunofluorescence patterns. J Clin Pathol 1999;52(2):124-8
   PubMed Web of Science ®Google Scholar
• Gaskin G, Savage COS, Ryan JJ, et al. Anti-neutrophil cytoplasmic antibodies and disease activity during long-term follow-up of 70 patients with systemic vasculitis. Nephrol Dial Transplant 1991;6(10):689-94
   PubMed Web of Science ®Google Scholar
• Specks U, Wheatley CL, McDonald TJ, et al. Anticytoplasmic autoantibodies in the diagnosis and follow-up of Wegener's granulomatosis. In: Mayo Clinic Proceedings. Elsevier; 1989. p. 28-36
   Google Scholar
• Tervaert JWC, van der Woude FJ, Fauci AS, et al. Association between active Wegener’s granulomatosis and anticytoplasmic antibodies. Arch Intern Med 1989;149(11):2461-5
   PubMed Web of Science ®Google Scholar
• Boomsma MM, Stegeman CA, van der Leij MJ, et al. Prediction of relapses in Wegener’s granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study. Arthritis Rheum 2000;43(9):2025-33
   PubMed Web of Science ®Google Scholar
• Kyndt X, Reumaux D, Bridoux F, et al. Serial measurements of antineutrophil cytoplasmic autoantibodies in patients with systemic vasculitis. Am J Med 1999;106(5):527-33
   PubMed Web of Science ®Google Scholar
• Lionaki S, Blyth ER, Hogan SL, et al. Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis. Arthritis Rheum 2012;64(10):3452-62
   PubMed Web of Science ®Google Scholar
• Han WK, Choi HK, Roth RM, et al. Serial ANCA titers: useful tool for prevention of relapses in ANCA-associated vasculitis. Kidney Int 2003;63(3):1079-85
   PubMed Web of Science ®Google Scholar
• Stasi R, Stipa E, Del Poeta G, et al. Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab. Rheumatology 2006;45(11):1432-6
   PubMed Web of Science ®Google Scholar
• Holding S, Fisher VJ, Abuzakouk M. Incidence of PR3-and MPO-ANCA autoantibody specificity changes in ANCA-associated vasculitis. Ann Clin Biochem 2015;52(Pt 2):297-301
   PubMed Web of Science ®Google Scholar
• Rao JK, Weinberger M, Oddone EZ, et al. The role of antineutrophil cytoplasmic antibody (c-ANCA) testing in the diagnosis of Wegener granulomatosis: a literature review and meta-analysis. Ann Intern Med 1995;123(12):925-32
   PubMed Web of Science ®Google Scholar
• Nolle B, Specks U, Lüdemann J, et al. Anticytoplasmic autoantibodies: their immunodiagnostic value in Wegener granulomatosis. Ann Intern Med 1989;111(1):28-40
   PubMed Web of Science ®Google Scholar
• Koenig W, Sund M, Fröhlich M, et al. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999;99(2):237-42
   PubMed Web of Science ®Google Scholar
• Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001;103(13):1813-18
   PubMed Web of Science ®Google Scholar
• Egner W, Chapel HM. Titration of antibodies against neutrophil cytoplasmic antigens is useful in monitoring disease activity in systemic vasculitides. Clin Exp Immunol 1990;82(2):244-9
   PubMed Web of Science ®Google Scholar
• Lally L, Spiera R. Current landscape of antineutrophil cytoplasmic antibody-associated vasculitis: classification, diagnosis, and treatment. Rheum Dis Clin North Am 2015;41(1):1-19
   PubMed Web of Science ®Google Scholar
• Kain R, Tadema H, McKinney EF, et al. High prevalence of autoantibodies to hLAMP-2 in anti–neutrophil cytoplasmic antibody–associated vasculitis. J Am Soc Nephrol 2012;23(3):556-66
   PubMed Web of Science ®Google Scholar
• Régent A, Lofek S, Dib H, et al. Identification of target antigens of anti-endothelial cell antibodies in patients with anti-neutrophil cytoplasmic antibody-associated vasculitides: a proteomic approach. Clin Immunol 2014;153(1):123-35
   PubMed Web of Science ®Google Scholar
• Podolsky DK. Inflammatory bowel disease. N Engl J Med 1991;325(13):928-37
   PubMed Web of Science ®Google Scholar
• Hanauer SB. Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis 2006;12(5):S3-9
   PubMedGoogle Scholar
• Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007;448(7152):427-34
   PubMed Web of Science ®Google Scholar
• Loftus Jr EV. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 2004;126(6):1504-17
   PubMed Web of Science ®Google Scholar
• Burisch J, Pedersen N, Čuković-Čavka S, et al. East–West gradient in the incidence of inflammatory bowel disease in Europe: the ECCO-EpiCom inception cohort. Gut 2014;63(4):588-97
   PubMed Web of Science ®Google Scholar
• Ng SC, Tang W, Ching JY, et al. Incidence and phenotype of inflammatory bowel disease based on results from the Asia-pacific Crohn’s and colitis epidemiology study. Gastroenterology 2013;145(1):158-65
   PubMed Web of Science ®Google Scholar
• Rahier J-F, Ben-Horin S, Chowers Y, et al. European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohn’s Colitis 2009;3(2):47-91
   Google Scholar
• Quinton JF, Sendid B, Reumaux D, et al. Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut 1998;42(6):788-91
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Loftus EV, Colombel JF, et al. Evaluation of serologic disease markers in a population-based cohort of patients with ulcerative colitis and Crohn’s disease. Inflamm Bowel Dis 2001;7(3):192-201
   PubMed Web of Science ®Google Scholar
• Zhou F, Xia B, Wang F, et al. The prevalence and diagnostic value of perinuclear antineutrophil cytoplasmic antibodies and anti-Saccharomyces cerevisiae antibodies in patients with inflammatory bowel disease in mainland China. Clin Chim Acta 2010;411(19–20):1461-5
   PubMed Web of Science ®Google Scholar
• Homšak E, Mičetić-Turk D, Božič B. Autoantibodies pANCA, GAB and PAB in inflammatory bowel disease: prevalence, characteristics and diagnostic value. Wien Klin Wochenschr 2010;122(2):19-25
   PubMedGoogle Scholar
• Kovacs M, Lakatos PL, Papp M, et al. Pancreatic autoantibodies and autoantibodies against goblet cells in pediatric patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2012;55(4):429-35
   PubMed Web of Science ®Google Scholar
• Mokhtarifar A, Ganji A, Sadrneshin M, et al. Diagnostic value of ASCA and atypical p-ANCA in differential diagnosis of inflammatory bowel disease. Middle East J Dig Dis 2013;5(2):93
   PubMedGoogle Scholar
• Kharitonov AG, Kondrashina EA, Baranovskii A, et al. [The clinical immunologic characteristics of different variants of course of ulcer colitis]. Klin Lab Diagn 2013(3):22-6
   PubMedGoogle Scholar
• Mahler M, Bogdanos DP, Pavlidis P, et al. PR3-ANCA: a promising biomarker for ulcerative colitis with extensive disease. Clin Chim Acta 2013;424:267-73
   PubMed Web of Science ®Google Scholar
• Saxon A, Shanahan F, Landers C, et al. A distinct subset of antineutrophil cytoplasmic antibodies is associated with inflammatory bowel disease. J Allergy Clin Immunol 1990;86(2):202-10
   PubMed Web of Science ®Google Scholar
• Rump JA, Schölmerich J, Gross V, et al. A new type of perinuclear anti-neutrophil cytoplasmic antibody (p-ANCA) in active ulcerative colitis but not in Crohn’s disease. Immunobiology 1990;181(4–5):406-13
   PubMed Web of Science ®Google Scholar
• Peeters M, Joossens S, Vermeire S, et al. Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease. Am J Gastroenterol 2001;96(3):730-4
   PubMed Web of Science ®Google Scholar
• Pool MO, Ellerbroek PM, Ridwan BU, et al. Serum antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease are mainly associated with ulcerative colitis. A correlation study between perinuclear antineutrophil cytoplasmic autoantibodies and clinical parameters, medical, and surgical treatment. Gut 1993;34(1):46-50
   PubMed Web of Science ®Google Scholar
• Seibold F, Weber P, Klein R, et al. Clinical significance of antibodies against neutrophils in patients with inflammatory bowel disease and primary sclerosing cholangitis. Gut 1992;33(5):657-62
   PubMed Web of Science ®Google Scholar
• Desplat-Jégo S, Johanet C, Escande A, et al. Update on Anti-Saccharomyces cerevisiae antibodies, anti-nuclear associated anti-neutrophil antibodies and antibodies to exocrine pancreas detected by indirect immunofluorescence as biomarkers in chronic inflammatory bowel diseases: results of a multicenter study. World J Gastroenterol 2007;13(16):2312-18
   PubMed Web of Science ®Google Scholar
• Hardarson S, Labrecque DR, Mitros FA, et al. Antineutrophil cytoplasmic antibody in inflammatory bowel and hepatobiliary diseases. High prevalence in ulcerative colitis, primary sclerosing cholangitis, and autoimmune hepatitis. Am J Clin Pathol 1993;99(3):277-81
   PubMed Web of Science ®Google Scholar
• Vasiliauskas EA, Kam LY, Karp LC, et al. Marker antibody expression stratifies Crohn’s disease into immunologically homogeneous subgroups with distinct clinical characteristics. Gut 2000;47(4):487-96
   PubMed Web of Science ®Google Scholar
• Terjung B, Spengler U, Sauerbruch T, et al. “Atypical p-ANCA” in IBD and hepatobiliary disorders react with a 50-kilodalton nuclear envelope protein of neutrophils and myeloid cell lines. Gastroenterology 2000;119(2):310-22
   PubMed Web of Science ®Google Scholar
• Halbwachs-Mecarelli L, Nusbaum P, Noel LH, et al. Antineutrophil cytoplasmic antibodies (ANCA) directed against cathepsin G in ulcerative colitis, Crohn’s disease and primary sclerosing cholangitis. Clin Exp Immunol 1992;90(1):79-84
   PubMed Web of Science ®Google Scholar
• Lakatos PL, Altorjay I, Szamosi T, et al. Pancreatic autoantibodies are associated with reactivity to microbial antibodies, penetrating disease behavior, perianal disease, and extraintestinal manifestations, but not with NOD2/CARD15 or TLR4 genotype in a Hungarian IBD cohort. Inflamm Bowel Dis 2009;15(3):365-74
   PubMed Web of Science ®Google Scholar
• Stocker W, Otte M, Ulrich S, et al. [Autoantibodies against the exocrine pancreas and against intestinal goblet cells in the diagnosis of Crohn’s disease and ulcerative colitis]. Dtsch Med Wochenschr (1946) 1984;109(51-52):1963-9
   PubMed Web of Science ®Google Scholar
• Seibold F, Weber P, Jenss H, et al. Antibodies to a trypsin sensitive pancreatic antigen in chronic inflammatory bowel disease: specific markers for a subgroup of patients with Crohn’s disease. Gut 1991;32(10):1192-7
   PubMed Web of Science ®Google Scholar
• Stöcker W, Otte M, Ulrich S, et al. Autoimmunity to pancreatic juice in Crohn’s disease. Results of an autoantibody screening in patients with chronic inflammatory bowel disease. Scand J Gastroenterol Suppl 1987;22(S139):41-52
   Google Scholar
• Roggenbuck D, Hausdorf G, Martinez-Gamboa L, et al. Identification of GP2, the major zymogen granule membrane glycoprotein, as the autoantigen of pancreatic antibodies in Crohn’s disease. Gut 2009;58(12):1620-8
   PubMed Web of Science ®Google Scholar
• De Beéck KO, Vermeire S, Rutgeerts P, et al. Antibodies to GP2, the major zymogen granule membrane glycoprotein, in inflammatory bowel diseases. Gut 2012;61(1):162-4
   Web of Science ®Google Scholar
• Roggenbuck D, Reinhold D, Wex T, et al. Autoantibodies to GP2, the major zymogen granule membrane glycoprotein, are new markers in Crohn’s disease. Clin Chim Acta 2011;412(9):718-24
   PubMed Web of Science ®Google Scholar
• Ruemmele FM, Targan SR, Levy G, et al. Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease. Gastroenterology 1998;115(4):822-9
   PubMed Web of Science ®Google Scholar
• Gao F, Aheman A, Lu JJ, et al. Association of HLA-DRB1 alleles and anti-neutrophil cytoplasmic antibodies in Han and Uyghur patients with ulcerative colitis in China. J Dig Dis 2014;15(6):299-305
   PubMed Web of Science ®Google Scholar
• Vasiliauskas EA, Plevy SE, Landers CJ, et al. Perinuclear antineutrophil cytoplasmic antibodies in patients with Crohn’s disease define a clinical subgroup. Gastroenterology 1996;110(6):1810-19
   PubMed Web of Science ®Google Scholar
• Taylor KD, Yang H, Landers CJ, et al. ANCA pattern and LTA haplotype relationship to clinical responses to anti-TNF antibody treatment in Crohn’s disease. Gastroenterology 2001;120(6):1347-55
   PubMed Web of Science ®Google Scholar
• Ferrante M, Henckaerts L, Joossens M, et al. New serological markers in inflammatory bowel disease are associated with complicated disease behaviour. Gut 2007;56(10):1394-403
   PubMed Web of Science ®Google Scholar
• Bossuyt X. Serologic markers in inflammatory bowel disease. Clin Chem 2006;52(2):171-81
   PubMed Web of Science ®Google Scholar
• Prideaux L, De Cruz P, Ng SC, et al. Serological antibodies in inflammatory bowel disease: a systematic review. Inflamm Bowel Dis 2012;18(7):1340-55
   PubMed Web of Science ®Google Scholar
• Arias-Loste MT, Bonilla G, Moraleja I, et al. Presence of anti-proteinase 3 antineutrophil cytoplasmic antibodies (anti-PR3 ANCA) as serologic markers in inflammatory bowel disease. Clin Rev Allergy Immunol 2013;45(1):109-16
   PubMed Web of Science ®Google Scholar
• Cooper GS, Stroehla BC. The epidemiology of autoimmune diseases. Autoimmun Rev 2003;2(3):119-25
   PubMed Web of Science ®Google Scholar
• Ferri C, Valentini G, Cozzi F, et al. Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine 2002;81(2):139-53
   PubMed Web of Science ®Google Scholar
• Tan EM, Rodnan GP, Garcia I, et al. Diversity of antinuclear antibodies in progressive systemic sclerosis. Arthritis Rheum 1980;23(6):617-25
   PubMedGoogle Scholar
• Catoggio LJ, Bernstein RM, Black CM, et al. Serological markers in progressive systemic sclerosis: clinical correlations. Ann Rheum Dis 1983;42(1):23-7
   PubMed Web of Science ®Google Scholar
• Steen VD. Autoantibodies in systemic sclerosis. In: Seminars in arthritis and rheumatism. WB Saunders; 2005. p. 35-42
   Google Scholar
• Hudson M, Mahler M, Pope J, et al. Clinical correlates of CENP-A and CENP-B antibodies in a large cohort of patients with systemic sclerosis. J Rheumatol 2012;39(4):787-94
   PubMed Web of Science ®Google Scholar
• Avouac J, Fransen J, Walker UA, et al. Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group. Ann Rheum Dis 2011;70(3):476-81
   PubMed Web of Science ®Google Scholar
• Shanmugam V, Swistowski D, Saddic N, et al. Comparison of indirect immunofluorescence and multiplex antinuclear antibody screening in systemic sclerosis. Clin Rheumatol 2011;30(10):1363-8
   PubMed Web of Science ®Google Scholar
• Kivity S, Gilburd B, Agmon-Levin N, et al. A novel automated indirect immunofluorescence autoantibody evaluation. Clin Rheumatol 2012;31(3):503-9
   PubMed Web of Science ®Google Scholar
• Mahler M, You D, Baron M, et al. Anti-centromere antibodies in a large cohort of systemic sclerosis patients: comparison between immunofluorescence, CENP-A and CENP-B ELISA. Clin Chim Acta 2011;412(21–22):1937-43
   PubMed Web of Science ®Google Scholar
• Ii RWK, Fertig N, Lucas MR, et al. Anti-PM-Scl antibody in patients with systemic sclerosis. Clin Exp Rheumatol 2012;30(71):S12-16
   PubMedGoogle Scholar
• Hamaguchi Y. Autoantibody profiles in systemic sclerosis: predictive value for clinical evaluation and prognosis. J Dermatol 2010;37(1):42-53
   PubMed Web of Science ®Google Scholar
• Mehra S, Walker J, Patterson K, et al. Autoantibodies in systemic sclerosis. Autoimmun Rev 2013;12(3):340-54
   PubMed Web of Science ®Google Scholar
• Mihai C, Tervaert JWC. Anti-endothelial cell antibodies in systemic sclerosis. Ann Rheum Dis 2010;69(2):319-24
   PubMed Web of Science ®Google Scholar
• Dib H, Tamby MC, Bussone G, et al. Targets of anti-endothelial cell antibodies in pulmonary hypertension and scleroderma. Eur Respir J 2012;39(6):1405-14
   PubMed Web of Science ®Google Scholar
• Krawitt EL. Autoimmune hepatitis. N Engl J Med 2006;354(1):54-66
   PubMed Web of Science ®Google Scholar
• Blachier M, Leleu H, Peck-Radosavljevic M, et al. The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol 2013;58(3):593-608
   PubMed Web of Science ®Google Scholar
• Boberg KM, Chapman RW, Hirschfield GM, et al. Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue. J Hepatol 2011;54(2):374-85
   PubMed Web of Science ®Google Scholar
• Hennes EM, Zeniya M, Czaja A, et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008;48(1):169-76
   PubMed Web of Science ®Google Scholar
• Czaja AJ, Cassani F, Cataleta M, et al. Antinuclear antibodies and patterns of nuclear immunofluorescence in type 1 autoimmune hepatitis. Dig Dis Sci 1997;42(8):1688-96
   PubMed Web of Science ®Google Scholar
• Cassani F, Cataleta M, Valentini P, et al. Serum autoantibodies in chronic hepatitis C: comparison with autoimmune hepatitis and impact on the disease profile. Hepatology 1997;26(3):561-6
   PubMed Web of Science ®Google Scholar
• Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999;31(5):929-38
   PubMed Web of Science ®Google Scholar
• Czaja AJ, Nishioka M, Morshed SA, et al. Patterns of nuclear immunofluorescence and reactivities to recombinant nuclear antigens in autoimmune hepatitis. Gastroenterology 1994;107(1):200-7
   PubMed Web of Science ®Google Scholar
• Czaja AJ, Cassani F, Cataleta M, et al. Frequency and significance of antibodies to actin in type 1 autoimmune hepatitis. Hepatology 1996;24(5):1068-73
   PubMed Web of Science ®Google Scholar
• Targan SR, Landers C, Vidrich A, et al. High-titer antineutrophil cytoplasmic antibodies in type-1 autoimmune hepatitis. Gastroenterology 1995;108(4):1159-66
   PubMed Web of Science ®Google Scholar
• Zauli D, Ghetti S, Grassi A, et al. Anti-neutrophil cytoplasmic antibodies in type 1 and 2 autoimmune hepatitis. Hepatology 1997;25(5):1105-7
   PubMed Web of Science ®Google Scholar
• Muratori L, Cataleta M, Muratori P, et al. Liver/kidney microsomal antibody type 1 and liver cytosol antibody type 1 concentrations in type 2 autoimmune hepatitis. Gut 1998;42(5):721-6
   PubMed Web of Science ®Google Scholar
• Czaja AJ. Behavior and significance of autoantibodies in type 1 autoimmune hepatitis. J Hepatol 1999;30(3):394-401
   PubMed Web of Science ®Google Scholar
• Johanet C, Ballot E. Autoantibodies in autoimmune hepatitis: anti-liver kidney microsome type 1 (anti-LKM1) and anti-liver cytosol type 1 (anti-LC1) antibodies. Clin Res Hepatol Gastroenterol 2013;37(2):216-18
   PubMed Web of Science ®Google Scholar
• Kaplan MM, Gershwin ME. Primary biliary cirrhosis. N Engl J Med 2005;353(12):1261-73
   PubMed Web of Science ®Google Scholar
• Boonstra K, Beuers U, Ponsioen CY. Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review. J Hepatol 2012;56(5):1181-8
   PubMed Web of Science ®Google Scholar
• Poupon R. Primary biliary cirrhosis: a 2010 update. J Hepatol 2010;52(5):745-58
   PubMed Web of Science ®Google Scholar
• Invernizzi P, Crosignani A, Battezzati PM, et al. Comparison of the clinical features and clinical course of antimitochondrial antibody-positive and -negative primary biliary cirrhosis. Hepatology 1997;25(5):1090-5
   PubMed Web of Science ®Google Scholar
• Goudie RB, MacSween RNM, Goldberg DM. Serological and histological diagnosis of primary biliary cirrhosis. J Clin Pathol 1966;19(6):527-38
   PubMed Web of Science ®Google Scholar
• Wesierska-Gadek J, Penner E, Battezzati PM, et al. Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis. Hepatology 2006;43(5):1135-44
   PubMed Web of Science ®Google Scholar
• Rigopoulou EI, Davies ET, Pares A, et al. Prevalence and clinical significance of isotype specific antinuclear antibodies in primary biliary cirrhosis. Gut 2005;54(4):528-32
   PubMed Web of Science ®Google Scholar
• Muratori P, Muratori L, Ferrari R, et al. Characterization and clinical impact of antinuclear antibodies in primary biliary cirrhosis. Am J Gastroenterol 2003;98(2):431-7
   PubMed Web of Science ®Google Scholar
• Mitchison HC, Bassendine MF, Hendrick A, et al. Positive antimitochondrial antibody but normal alkaline phosphatase: is this primary biliary cirrhosis? Hepatology 1986;6(6):1279-84
   PubMed Web of Science ®Google Scholar
• Klatskin G, Kantor FS. Mitochondrial antibody in primary biliary cirrhosis and other diseases. Ann Intern Med 1972;77(4):533-41
   PubMed Web of Science ®Google Scholar
• Invernizzi P, Selmi C, Ranftler C, et al. Antinuclear antibodies in primary biliary cirrhosis. Thieme Medical Publishers, Inc; New York, NY, USA: 2005. p. 298-310
   Google Scholar
• Corpechot C, Abenavoli L, Rabahi N, et al. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology 2008;48(3):871-7
   PubMed Web of Science ®Google Scholar
• Agmon-Levin N, Mosca M, Petri M, et al. Systemic lupus erythematosus one disease or many? Autoimmun Rev 2012;11(8):593-5
   PubMed Web of Science ®Google Scholar
• Cervera R, Khamashta MA, Font J, et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine 2003;82(5):299-308
   PubMed Web of Science ®Google Scholar
• Unterman A, Nolte JES, Boaz M, et al. Neuropsychiatric syndromes in systemic lupus erythematosus: a meta-analysis. Semin Arthritis Rheum 2011;41(1):1-11
   PubMed Web of Science ®Google Scholar
• Bertsias GK, Ioannidis JPA, Aringer M, et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis 2010;69(12):2074-82
   PubMed Web of Science ®Google Scholar
• Jakes RW, Bae S-C, Louthrenoo W, et al. Systematic review of the epidemiology of systemic lupus erythematosus in the Asia-Pacific region: prevalence, incidence, clinical features, and mortality. Arthritis Care Res (Hoboken) 2012;64(2):159-68
   PubMed Web of Science ®Google Scholar
• Roman MJ, Shanker B-A, Davis A, et al. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003;349(25):2399-406
   PubMed Web of Science ®Google Scholar
• Pons-Estel GJ, Alarcón GS, Scofield L, et al. Understanding the epidemiology and progression of systemic lupus erythematosus. Semin Arthritis Rheum 2010;39(4):257-68
   PubMed Web of Science ®Google Scholar
• Arbuckle MR, McClain MT, Rubertone MV, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003;349(16):1526-33
   PubMed Web of Science ®Google Scholar
• Eriksson C, Kokkonen H, Johansson M, et al. Autoantibodies predate the onset of systemic lupus erythematosus in northern Sweden. Arthritis Res Ther 2011;13(1):R30
   PubMed Web of Science ®Google Scholar
• Sherer Y, Gorstein A, Fritzler MJ, et al. Autoantibody explosion in systemic lupus erythematosus: more than 100 different antibodies found in SLE patients. Semin Arthritis Rheum 2004;34(2):501-37
   PubMed Web of Science ®Google Scholar
• Petri M, Orbai A-M, Alarcón GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012;64(8):2677-86
   PubMed Web of Science ®Google Scholar
• Hoffman IEA, Peene I, Meheus L, et al. Specific antinuclear antibodies are associated with clinical features in systemic lupus erythematosus. Ann Rheum Dis 2004;63(9):1155-8
   PubMed Web of Science ®Google Scholar
• Schnabel A, Csernok E, Isenberg DA, et al. Antineutrophil cytoplasmic antibodies in systemic lupus erythematosus. Arthritis Rheum 1995;38(5):633-7
   PubMedGoogle Scholar
• Galeazzi M, Morozzi G, Sebastiani GD, et al. Anti-neutrophil cytoplasmic antibodies in 566 European patients with systemic lupus erythematosus: prevalence, clinical associations and correlation with other autoantibodies. European Concerted Action on the Immunogenetics of SLE. Clin Exp Rheumatol 1997;16(5):541-6
   Web of Science ®Google Scholar
• Li C, Mu R, Lu X-Y, et al. Antilymphocyte antibodies in systemic lupus erythematosus: association with disease activity and lymphopenia. J Immunol Res 2014;2014:672126
   PubMed Web of Science ®Google Scholar
• Fritzler M, Tan EM. Antibodies to histones in drug-induced and idiopathic lupus erythematosus. J Clin Invest 1978;62(3):560
   PubMed Web of Science ®Google Scholar
• Alamanos Y, Tsifetaki N, Voulgari PV, et al. Epidemiology of primary Sjögren’s syndrome in north-west Greece, 1982–2003. Rheumatology (Oxford) 2006;45(2):187-91
   PubMed Web of Science ®Google Scholar
• Fox RI. Sjögren’s syndrome. Lancet 2005;366(9482):321-31
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Tzioufas AG, Font J. Primary Sjögren’s syndrome: new clinical and therapeutic concepts. Ann Rheum Dis 2005;64(3):347-54
   PubMed Web of Science ®Google Scholar
• Jonsson R, Brun JG. Sjögren’s syndrome. John Wiley & Sons, Ltd; 2010
   Google Scholar
• Skopouli FN, Dafni U, Ioannidis JPA, et al. Clinical evolution, and morbidity and mortalityof primary Sjögren's syndrome. In: Seminars in arthritis and rheumatism. WB Saunders; 2000. p. 296-304
   Google Scholar
• Shiboski SC, Shiboski CH, Criswell LA, et al. American College of Rheumatology classification criteria for Sjögren’s syndrome: a data-driven, expert consensus approach in the Sjögren’s International Collaborative Clinical Alliance Cohort. Arthritis Care Res (Hoboken) 2012;64(4):475-87
   PubMed Web of Science ®Google Scholar
• Franceschini F, Cavazzana I. Anti-Ro/SSA and La/SSB antibodies. Autoimmunity 2005;38(1):55-63
   PubMed Web of Science ®Google Scholar
• Bournia V-K, Vlachoyiannopoulos PG. Subgroups of Sjögren syndrome patients according to serological profiles. J Autoimmun 2012;39(1):15-26
   PubMed Web of Science ®Google Scholar
• Bossuyt X, Frans J, Hendrickx A, et al. Detection of Anti-SSA Antibodies by Indirect Immunofluorescence. Clin Chem 2004;50(12):2361-9
   PubMed Web of Science ®Google Scholar
• Gottenberg J-E, Mignot S, Nicaise-Rolland P, et al. Prevalence of anti-cyclic citrullinated peptide and anti-keratin antibodies in patients with primary Sjögren’s syndrome. Ann Rheum Dis 2005;64(1):114-17
   PubMed Web of Science ®Google Scholar
• Font J, Ramos-Casals M, Cervera R, et al. Antineutrophil cytoplasmic antibodies in primary Sjögren’s syndrome: prevalence and clinical significance. Rheumatology 1998;37(12):1287-91
   Web of Science ®Google Scholar
• Ramos-Casals M, Solans R, Rosas J, et al. Primary Sjögren syndrome in Spain: clinical and immunologic expression in 1010 patients. Medicine 2008;87(4):210-19
   PubMed Web of Science ®Google Scholar
• Alexander EL, Arnett FC, Provost TT, et al. Sjögren’s syndrome: association of anti-Ro (SS-A) antibodies with vasculitis, hematologic abnormalities, and serologic hyperreactivity. Ann Intern Med 1983;98(2):155-9
   PubMed Web of Science ®Google Scholar
• Moll JWB, Markusse HM, Pijnenburg J, et al. Antineuronal antibodies in patients with neurologic complicat’lons of primary Sjögren’s syndrome. Neurology 1993;43(12):2574-4
   PubMed Web of Science ®Google Scholar
• Salliot C, Gottenberg J-E, Bengoufa D, et al. Anticentromere antibodies identify patients with Sjögren’s syndrome and autoimmune overlap syndrome. J Rheumatol 2007;34(11):2253-8
   PubMed Web of Science ®Google Scholar
• Bournia V-KK, Diamanti KD, Vlachoyiannopoulos PG, et al. Anticentromere antibody positive Sjögren’s Syndrome: a retrospective descriptive analysis. Arthritis Res Ther 2010;12(2):R47
   Web of Science ®Google Scholar
• Nakamura H, Kawakami A, Hayashi T, et al. Anti-centromere antibody-seropositive Sjögren’s syndrome differs from conventional subgroup in clinical and pathological study. BMC Musculoskelet Disord 2010;11(1):140
   PubMedGoogle Scholar
• Katano K, Kawano M, Koni I, et al. Clinical and laboratory features of anticentromere antibody positive primary Sjögren’s syndrome. J Rheumatol 2001;28(10):2238-44
   PubMed Web of Science ®Google Scholar
• Hartwell LH, Kastan MB. Cell cycle control and cancer. Science 1994;266(5192):1821-8
   PubMed Web of Science ®Google Scholar
• Celis JE, Celis A. Cell cycle-dependent variations in the distribution of the nuclear protein cyclin proliferating cell nuclear antigen in cultured cells: subdivision of S phase. Proc Natl Acad Sci USA 1985. 82(10):3262-6
   Google Scholar
• Fredi M, Cavazzana I, Quinzanini M, et al. Rare autoantibodies to cellular antigens in systemic lupus erythematosus. Lupus 2014. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Beyne-Rauzy O, Thébault S, Adoue D, et al. Anti-PCNA antibodies: prevalence and predictive value. Joint Bone Spine 2005;72(5):432-5
   PubMed Web of Science ®Google Scholar
• Fritzler MJ, McCarty GA, Paul Ryan J, et al. Clinical features of patients with antibodies directed against proliferating cell nuclear antigen. Arthritis Rheum 1983;26(2):140-5
   PubMedGoogle Scholar
• Takasaki Y, Fishwild D, Tan EM. Characterization of proliferating cell nuclear antigen recognized by autoantibodies in lupus sera. J Exp Med 1984;159(4):981-92
   PubMed Web of Science ®Google Scholar
• Mahler M, Miyachi K, Peebles C, et al. The clinical significance of autoantibodies to the proliferating cell nuclear antigen (PCNA). Autoimmun Rev 2012;11(10):771-5
   PubMed Web of Science ®Google Scholar
• Available from: www.ncbi.nlm.nih.gov/gene/1063
   Google Scholar
• Zhu X, Mancini MA, Chang KH, et al. Characterization of a novel 350-kilodalton nuclear phosphoprotein that is specifically involved in mitotic-phase progression. Mol Cell Biol 1995;15(9):5017-29
   PubMed Web of Science ®Google Scholar
• Rattner JB, Rees J, Whitehead CM, et al. High frequency of neoplasia in patients with autoantibodies to centromere protein CENP-F. Clin Invest Med 1997;20(5):308-19
   PubMed Web of Science ®Google Scholar
• Casiano CA, Humbel RL, Peebles C, et al. Autoimmunity to the cell cycle-dependent centromere protein p330d/CENP-F in disorders associated with cell proliferation. J Autoimmun 1995;8(4):575-86
   PubMed Web of Science ®Google Scholar
• Fritzler MJ, Rattner JB, Luft LM, et al. Historical perspectives on the discovery and elucidation of autoantibodies to centromere proteins (CENP) and the emerging importance of antibodies to CENP-F. Autoimmun Rev 2011;10(4):194-200
   PubMed Web of Science ®Google Scholar
• Mozo L, Gutierrez C, Gomez J. Antibodies to mitotic spindle apparatus: clinical significance of NuMA and HsEg5 autoantibodies. J Clin Immunol 2008;28(4):285-90
   PubMed Web of Science ®Google Scholar
• Szalat R, Ghillani-Dalbin P, Jallouli M, et al. Anti-NuMA1 and anti-NuMA2 (anti-HsEg5) antibodies: clinical and immunological features: a propos of 40 new cases and review of the literature. Autoimmun Rev 2010;9(10):652-6
   PubMed Web of Science ®Google Scholar
• Egerer K, Roggenbuck D, Hiemann R, et al. Automated evaluation of autoantibodies on human epithelial-2 cells as an approach to standardize cell-based immunofluorescence tests. Arthritis Res Ther 2010;12(2):R40
   PubMed Web of Science ®Google Scholar
• Melegari A, Bonaguri C, Russo A, et al. A comparative study on the reliability of an automated system for the evaluation of cell-based indirect immunofluorescence. Autoimmun Rev 2012;11(10):713-16
   PubMed Web of Science ®Google Scholar
• Rigon A, Buzzulini F, Soda P, et al. Novel opportunities in automated classification of antinuclear antibodies on HEp-2 cells. Autoimmun Rev 2011;10(10):647-52
   PubMed Web of Science ®Google Scholar
• Knütter I, Hiemann R, Brumma T, et al. Automated interpretation of ANCA patterns-a new approach in the serology of ANCA-associated vasculitis. Arthritis Res Ther 2012;14(6):R271
   Web of Science ®Google Scholar
• Meroni PL, Bizzaro N, Cavazzana I, et al. Automated tests of ANA immunofluorescence as throughput autoantibody detection technology: strengths and limitations. BMC Med 2014;12(1):38
   PubMedGoogle Scholar
• Hiemann R, Büttner T, Krieger T, et al. Challenges of automated screening and differentiation of non-organ specific autoantibodies on HEp-2 cells. Autoimmun Rev 2009;9(1):17-22
   PubMed Web of Science ®Google Scholar
• Bonroy C, Verfaillie C, Smith V, et al. Automated indirect immunofluorescence antinuclear antibody analysis is a standardized alternative for visual microscope interpretation. Clin Chem Lab Med 2013;51(9):1771-9
   PubMed Web of Science ®Google Scholar